Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 20, 2020

Verrica reports positive Phase III results of VP-102 in molluscum

Verrica Pharmaceuticals has reported positive results from the post-hoc pooled analysis of the Phase III CAMP clinical trials of VP-102 in patients with molluscum contagiosum.

Verrica Pharmaceuticals has reported positive results from the post-hoc pooled analysis of the Phase III CAMP clinical trials of VP-102 in patients with molluscum contagiosum.

Molluscum is a contagious viral skin infection, while VP-102 is a topical solution of 0.7% cantharidin being developed to treat the highly infectious disease.

The CAMP studies assessed the safety and efficacy of the drug candidate. The pooled analysis found statistically significantly higher clearance of all lesions in the VP-102 group.

During the analysis, efficacy was determined as the proportion of participants with complete clearance of lesions in each body location by visit.

The statistically significantly higher clearance with VP-102 was observed across all body regions, including head/neck, chest/abdomen, back/buttocks, as well as upper and lower extremities.

In addition, adverse event rates in patients treated with VP-102 were similar for all locations.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The incidence of treatment-emergent adverse events (TEAEs) was measured depending on application site reactions reported during or following treatment visit one and prior to visit two.

The most common TEAEs were application site vesicles, pruritus, pain, erythema, scab, discolouration, dryness and oedema.

VP-102 Phase III molluscum programme principal investigator Lawrence Eichenfield said: “The results of this study are important, as they suggest that this investigational molluscum treatment can potentially bring about complete clearance, regardless of where on the body the lesion is located.

“If approved, VP-102 may potentially be an important option for physicians, as they can have the option to treat even the most sensitive areas, including the groin, head, and neck.”

The company is presenting the post-hoc pooled analysis data at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast, Hawaii from 18-22 January.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU